Eczema cream study halted after just 3 volunteers
NCT ID NCT07146971
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small study tested an over-the-counter cream for atopic dermatitis (eczema) in just 3 people. Researchers looked at skin bacteria, hydration, and barrier function to see if the cream helped. The study was terminated early, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- OTC cosmetic cream formulation
- What this could lead to
- If it works, this could point toward a better understanding of how OTC creams affect skin microbiome and symptoms in atopic dermatitis.
- What could go wrong
- This was a tiny Phase 1 study with only 3 participants and was terminated early. Results may not be reliable or generalizable. The cream is not approved for treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
3 people
The number who actually took part.
- Started
-
Aug 2025
- Finished
-
May 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Previously diagnosed Atopic Dermatitis with active, visible flare-ups at time of screening * Present dry/itchy skin patches on forearm, back of the hand, or posterior lower leg suitable for treatment assessment * Evidence of inflammatory disease (documented diagnosis and current active symptoms) * Stable skincare routine for 4 weeks prior to screening * Subject willing to avoid conflicting topical treatments during study period * Subject being used to applying topical treatments for atopic dermatitis General: * Healthy subject apart from atopic dermatitis * Subject having given free informed, written consent * Subject willing to adhere to protocol and study procedures Exclusion Criteria: * Pregnant or nursing woman or woman planning to get pregnant during the study * Recent (within 4 weeks) or current history of using atopic dermatitis biological drugs, such as dupilumab, lebrikizumab, nemolizumab, and tralokinumab * Recent use of systemic antibiotics, steroids, or immunomodulators (within 4 weeks) * Active skin infections unrelated to atopic dermatitis * Severe dermatologic conditions requiring immediate medical intervention * Use of topical or systemic treatment during previous weeks liable to interfere with assessment * Subject having undergone surgery under general anaesthesia within the previous month * Excessive exposure to sunlight or UV-rays within the previous month * Subject having scars, tattoos on the forearms that would interfere with assessments * Subject enrolled in another clinical trial during the study period and/or during the past 30 days
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atopic dermatitis (AD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sequential Skin
New York, New York, 10013, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.